The objective of this proposal is to conduct indepth studies of tumor invasion and metastasis in two human tumor systems, malignant melanoma and neuroblastoma. This will be accomplished by two major approaches: First, by gaining a basic understanding of the complex processes at the biological and molecular levels, using at least five different antigens preferentually expressed on these neoplasms and already will established as effective targets for tumor destruction mediated by specific monoclonal antibodies. Second, by first optimizing and them combining individual treatment modalities to act synergistically in the destruction of human tumors and their mestastases in experimental animal model systems. These effects will combine manipulations of the host's immune system with targeting of chemotherapeutic drugs, radionuclides, differentiation agents and ribosome inactivating proteins (RIP) by monoclonal antibodies directed to effective tumor antigen targets. The basic rationale underlying this research proposal is to make use of monoclonal antibody-defined antigens on human melanoma and neuroblastoma cells that have already been established as effective targets for monoclonal antibody-mediated tumor destruction during the last five years of this laboratory's efforts. To render these systems optimally effective approaches will be used to gain further basic knowledge of tumor invasion and metastasis. Other experimental systems will be optimized with reagents and treatment modulities being combined to act most synergystically in the destruction of human melanoma and neuroblastoma metastases. It is anticipated that achievement of the objectives outlined here will result in a better understanding of tumor biology and hopefully provide new and effective modalities for the treatment of human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA042508-06
Application #
3479336
Study Section
Special Emphasis Panel (SRC)
Project Start
1986-06-01
Project End
1992-05-31
Budget Start
1991-06-01
Budget End
1992-05-31
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Shabat, D; Lode, H N; Pertl, U et al. (2001) In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci U S A 98:7528-33
Xiang, R; Silletti, S; Lode, H N et al. (2001) Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res 7:856s-864s
Lode, H N; Reisfeld, R A (2000) Targeted cytokines for cancer immunotherapy. Immunol Res 21:279-88
Xiang, R; Lode, H N; Chao, T H et al. (2000) An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A 97:5492-7
Lode, H N; Xiang, R; Pertl, U et al. (2000) Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest 105:1623-30
Balicki, D; Reisfeld, R A; Pertl, U et al. (2000) Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. Proc Natl Acad Sci U S A 97:11500-4
Lode, H N; Pertl, U; Xiang, R et al. (2000) Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 35:641-6
Lode, H N; Xiang, R; Duncan, S R et al. (1999) Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A 96:8591-6
Lode, H N; Moehler, T; Xiang, R et al. (1999) Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A 96:1591-6
Nayeem, N; Silletti, S; Yang, X et al. (1999) A potential role for the plasmin(ogen) system in the posttranslational cleavage of the neural cell adhesion molecule L1. J Cell Sci 112 ( Pt 24):4739-49

Showing the most recent 10 out of 70 publications